Imatinib Mesylate

DESCRIPTION

Imatinib is a 2-phenyl animo pyrimidine derivate and tyrosine-kinase inhibitor that is used in the treatment of a variety of cancers. It binds close to the ATP binding site of Bcr-Abl, inhibiting its activity. It is also reported to be used to inhibit stem cell proliferation and erythropoiesis.

DETAILS

Purity: ≥98%
Synonyms: Gleevec, Glivec, imatinib, imatinib methanesulfonate, STI571, STI-571
Cas Number: 220127-57-1
References: Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., ... & Joensuu, H. (2002). Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. New England Journal of Medicine, 347(7), 472-480. Talpaz, M., Silver, R. T., Druker, B. J., Goldman, J. M., Gambacorti-Passerini, C., Guilhot, F., ... & Sawyers, C. L. (2002). Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood, 99(6), 1928-1937. Gal, H., Pandi, G., Kanner, A. A., Ram, Z., Lithwick-Yanai, G., Amariglio, N., ... & Givol, D. (2008). MIR-451 and Imatinib mesylate inhibit tumor growth of Glioblastoma stem cells. Biochemical and biophysical research communications, 376(1), 86-90. O'Sullivan, S., Naot, D., Callon, K., Porteous, F., Horne, A., Wattie, D., ... & Grey, A. (2007). Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell‐dependent mechanisms. Journal of Bone and Mineral Research, 22(11), 1679-1689.
Application: FA
Formulation: Crystalline solid
Chemical Name: 4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide
Molecular Weight: 589.7
Molecular Formula: C29H31N7O CH4SO3
Storage Conditions: Product should be kept at -20°C.
Pubchem Openeye Can Smiles: CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5.CS(=O)(=O)O